Validation of the immunohistochemical expression of Programmed Death Ligand 1 (PD-L1) on cytological smears in advanced Non Small Cell Lung Cancer

The assessment of PD-L1 expression by immunohistochemistry (IHC) is mandatory for the treatment as first-line therapy with the anti PD-1 check-point inhibitor Pembrolizumab in patients with advanced non small-cell lung cancer (NSCLC). [1] The IHC cut-offs for the administration of Pembrolizumab in first- or second-line of therapy derive from the registration studies KEYNOTE-024 and 010 and have been stated as ≥50% PD-L1+ cells and ≥1% for first and second-line treatment, respectively. Several antibodies have been developed as companion diagnostics for the IHC predictive detection of PD-L1 in NSCLC tissue samples.

Source: Lung Cancer - October 17, 2018 Category: Cancer & Oncology Authors: Elisa Capizzi, Costantino Ricci, Francesca Giunchi, Stefano Zagnoni, Claudio Ceccarelli, Bego ña Urrios Álvarez Gómez, Laura Casolari, Francesco Gelsomino, Rocco Trisolini, Michelangelo Fiorentino, Andrea Ardizzoni Source Type: research